comparemela.com

Latest Breaking News On - Multisociety guideline - Page 1 : comparemela.com

Is it time to deprescribe lifetime beta-blockers for chronic coronary disease?

Over the last 50 years, revascularization and pharmacotherapeutic innovations have led to significant reductions in major adverse CV events associated with both acute and chronic coronary diseases. In historic acute MI trials, long-term use of beta-blockers has led to large reductions in major adverse CV events (MACE). These trials laid the foundation for the widespread and often lifelong use of

Precision testing strategy strongly benefits stable patients with suspected CAD

CHICAGO — In stable symptomatic patients with suspected CAD, a precision testing strategy was linked to a 70% reduction in death, MI or catheterization without obstructive CAD at 1 year compared with the usual testing, researchers reported.For the PRECISE trial, presented at the American Heart Association Scientific Sessions, Pamela S. Douglas, MD, MACC, FASE, FAHA, Ursula Geller Professor

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.